Rusty Field

Upsher-Smith, NASPA honor pharmacists

Upsher-Smith, NASPA honor pharmacists

MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. and the National Alliance of State Pharmacy Associations (NASPA) have recognized the efforts 43 pharmacists from across the nation with the 2016 NASPA Excellence in Innovation Award. Upsher-Smith said Wednesday that the pharmacists were honored for their outstanding contributions to the pharmacy profession. Sponsored by Upsher-Smith, the award is

Upsher-Smith rolls out Qudexy XR savings program

Upsher-Smith rolls out Qudexy XR savings program

MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. has launched a new savings and support program for Qudexy XR extended-release capsules, a once-daily, broad-spectrum anti-epileptic medication. Dubbed the “It’s That Simple” program, the initiative is designed to make it easier for doctors to prescribe Qudexy XR (topiramate) and includes a $0 co-payment for eligible patients. Qudexy XR is

Upsher-Smith, NASPA honor pharmacists

Upsher-Smith, NASPA honor pharmacists

MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. and the National Alliance of State Pharmacy Associations (NASPA) have recognized 43 pharmacists from across the country with a 2015 NASPA Excellence in Innovation Award. Upsher-Smith said the pharmacists were honored for their outstanding contributions to the pharmacy profession. More specifically, the Excellence in Innovation Award recognizes pharmacists who

Upsher-Smith promotes Field to president

Upsher-Smith promotes Field to president

MAPLE GROVE, Minn. — Rusty Field, chief commercial officer at Upsher-Smith Laboratories Inc., has been appointed as president of the company. Upsher-Smith said Monday that in the new role, Field will be responsible for delivering revenue and profitability to meet the pharmaceutical company’s growth objectives. He reports directly to chief executive officer Mark Evenstad. “During

Upsher-Smith gains approval for Namenda generic

MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. has received approval from the Food and Drug Administration of an Abbreviated New Drug Application (ANDA) for memantine hydrochloride tablets, a treatment for Alzheimer’s disease, in strengths of 5 mg and 10 mg. Upsher-Smith said Monday that its product is a generic version of Namenda from Forest Laboratories,